BOSTON BUSINESS JOURNAL – The last five years have seen a flurry of dealmaking in the medical device industry. And according to a new report, Marlborough-based Boston Scientific is responsible for more acquisitions than any other company since 2012 except one.
With 27,000 employees worldwide and around 2,500 here in Massachusetts, Boston Scientific (NYSE: BSX) is the largest medical device firm based in the state by headcount. It’s pulled off eight acquisitions since the beginning of 2012, according to the report by market research firm CB Insights. (The actual number appears to be 10; the report appears to omit one recent deal for an endoscopy firm and another in 2014 for a manufacturer.)
The only medical device company that was more active during this period was Boston Scientific’s rival, Ireland-based Medtronic (NYSE: MDT), which acquired a whopping 15 device firms.
For Boston Scientific, the string of acquisitions has coincided with the tenure of Mike Mahoney, who joined as president in October 2011 and was named CEO a year later. Boston Scientific has seen its stock price increase steadily with the 52-year-old Mahoney at the helm. He remains one of the highest-paid executives among public companies in the state, earning $35.7 million in total compensation plus value realized from past stock awards in 2016.
As of Thursday afternoon, Boston Scientific had a market capitalization of around $36 billion.
Here are the acquisitions by Boston Scientific since January 2012:
- California-based Cameron Health, $150 million plus more than $1 billion in potential milestone payments (March 2012)
- Minnesota-based BridgePoint Medical, undisclosed (September 2012)
- Burlington, Mass.-based Rhythmia Medical, $90 million plus $175 million in potential milestone payments (October 2012)
- California-based Vessix Vascular, $125 million plus up to $300 million in potential milestone payments (November 2012)
- California-based IoGyn, $65 million (May 2014)
- Germany-based StarMedTech GmbH, undisclosed (February 2014)
- California-based Xlumena, $62.5 million plus a $12.5 million contingent payment (April 2015)
- Burlington, Mass.-based Cosman Medical, undisclosed (July 2016)
- Georgia-based EndoChoice Holdings, $210 million (September 2016)
- Switzerland-based Symetis, $435 million (March 2017)
This article by Max Stendahl originally appeared here.